Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | TFPI2 | P48307 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | PPM1B | O75688 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PPP1CC | P36873 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9880160 | 0.87 | TSHR (0.54) | TSHRATMSMN1; SMN2TFPI2HPGD | |
| SCHEMBL19177682 | 0.85 | TSHR (0.40) | TSHRATMSMN1; SMN2TFPI2PPM1B | |
| SCHEMBL12390011 | 0.83 | TFPI2 (0.42) | TSHRTFPI2HSD11B1HPGDALDH1A1 | |
| SCHEMBL9880141 | 0.81 | TFPI2 (0.56) | TFPI2HSD11B1HPGDALDH1A1PPM1B | |
| SCHEMBL2005428 | 0.80 | PPM1B (0.44) | TSHRALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL9696402 | 0.80 | PPM1B (0.44) | TSHRALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL2002666 | 0.80 | PPM1B (0.44) | TSHRALDH1A1PPM1BPTPN1PPP1CC | |
| SCHEMBL12122109 | 0.80 | TFPI2 (0.42) | TSHRSMN1; SMN2TFPI2HSD11B1HPGD | |
| SCHEMBL9880175 | 0.77 | TFPI2 (0.59) | TSHRATMSMN1; SMN2TFPI2HSD11B1 | |
| SCHEMBL1008906 | 0.73 | PPM1B (0.56) | TSHRALDH1A1PPM1BPTPN1PPP1CC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9833450-B2 | Oxabicycloheptanes and oxabicycloheptenes for the treatment of depressive and stress disorders | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-12-05 | — | — | US | disclosed |
| US-20170340628-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-11-30 | — | — | US | disclosed |
| US-20170209434-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | H LEE MOFFITT CANCER CT & RES (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170136008-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF OVARIAN CANCER | LIXTE BIOTECHNOLOGY, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-20160303115-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DEPRESSIVE AND STRESS DISORDERS | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-10-20 | — | — | US | disclosed |
| US-20160074390-A1 | HUMAN DOSING OF PHOSPHATASE INHIBITOR | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| US-9079917-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2015-07-14 | — | — | US | disclosed |
| US-20150174123-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF REPERFUSION INJURY | LIXTE BIOTECHNOLOGY, INC. (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150148353-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | LIXTE BIOTECHNOLOGY, INC. (US) | 2015-05-28 | — | — | US | disclosed |
| US-20150045373-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. | 2015-02-12 | — | — | US | disclosed |
| US-8822461-B2 | Oxabicycloheptanes and oxabicycloheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. (US) | 2014-09-02 | — | — | US | disclosed |
| US-20140235649-A1 | USE OF PHOSPHATASE INHIBITORS OR HISTONE DEACETYLASE INHIBITORS TO TREAT DISEASES CHARACTERIZED BY LOSS OF PROTEIN FUNCTION | LIXTE BIOTECHNOLOGY, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20130302402-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | LIXTE BIOTECHNOLOGY, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20120135522-A1 | METHODS OF MODULATING CELL REGULATION BY INHIBITING P53 | LIXTE BIOTECHNOLOGY, INC. | 2012-05-31 | — | — | US | disclosed |
| US-8058268-B2 | Neuroprotective agents for the prevention and treatment of neurodegenerative diseases | LIXTE BIOTECHNOLOGY, INC. (US) | 2011-11-15 | — | — | US | disclosed |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074390-A1 | HUMAN DOSING OF PHOSPHATASE INHIBITOR | PPM1A, PPP2R2A, PPM1B | TSHR 2317/4885ATM 2344/4885SMN1; SMN2 2398/4885 |
| US-20140235649-A1 | USE OF PHOSPHATASE INHIBITORS OR HISTONE DEACETYLASE INHIBITORS TO TREAT DISEASES CHARACTERIZED BY LOSS OF PROTEIN FUNCTION | HDAC1, PPP3CA, PPM1A | TSHR 4100/4885ATM 2579/4885SMN1; SMN2 449/4885 |
| US-20170136008-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF OVARIAN CANCER | OAT, OGG1, OTC | TSHR 2379/4885ATM 1053/4885SMN1; SMN2 4003/4885 |
| US-20150045373-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | HCCS, OXA1L, OTC | TSHR 1659/4885ATM 4401/4885SMN1; SMN2 2484/4885 |
| US-20130302402-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE | HCCS, OXA1L, OTC | TSHR 1659/4885ATM 4401/4885SMN1; SMN2 2484/4885 |
| US-20150148353-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES | PPP2CA, PPP6C, PPP3CA | TSHR 745/4885ATM 2057/4885SMN1; SMN2 3554/4885 |
| US-20090036309-A1 | Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use | HCCS, VHL, OXA1L | TSHR 2338/4885ATM 4617/4885SMN1; SMN2 3455/4885 |
| US-20170340628-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | PPP2CA, PPP2R2A, PPP3CA | TSHR 3625/4885ATM 172/4885SMN1; SMN2 837/4885 |
| US-20170209434-A1 | PROTEIN PHOSPHATASE 2A INHIBITORS FOR TREATING MYELODYSPLASTIC SYNDROMES | PPP2CA, PPP2R2A, PPM1A | TSHR 3796/4885ATM 279/4885SMN1; SMN2 1929/4885 |
| US-20150174123-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF REPERFUSION INJURY | PPP2CA, PPP4C, PPP3CA | TSHR 2927/4885ATM 1023/4885SMN1; SMN2 2685/4885 |
| US-20160303115-A1 | OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DEPRESSIVE AND STRESS DISORDERS | HSD17B11, HSD17B1, CRH | TSHR 845/4885ATM 3511/4885SMN1; SMN2 3124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.